Cogstate Ltd
CGS.AX provides healthcare diagnostics services and develops related technologies, generating revenue primarily through service contracts and product sales.
Business. CGS.AX is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is listed on the Australian Securities Exchange under the ticker CGS.AX. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a provider of healthcare diagnostic solutions.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CGS.AX is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is listed on the Australian Securities Exchange under the ticker CGS.AX. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a provider of healthcare diagnostic solutions.
CGS.AX maintains a strong liquidity position with a current ratio of 3.77 and a low debt-to-equity ratio of 0.01, indicating minimal leverage and a robust balance sheet. The company holds $23.19 million in cash and equivalents, which is a significant portion of its total assets of $64.77 million, supporting its operational flexibility.
In terms of profitability, CGS.AX reports a return on equity (ROE) of 21.18% and a return on assets (ROA) of 15.66%, both of which exceed the typical thresholds for financial health in the healthcare diagnostics industry. The company's operating income of $13.91 million and net income of $10.14 million reflect strong operational efficiency and effective cost management.
Geographically and segment-wise, CGS.AX's revenue is concentrated in its core healthcare diagnostics services, with no disclosed geographic breakdown. The company's primary revenue source is its service contracts and product sales, which are likely to be concentrated in its domestic market.
Looking ahead, CGS.AX is projected to maintain a stable growth trajectory, supported by its strong cash flow and low debt. The company's free cash flow of $10.02 million and operating cash flow of $11.48 million indicate a solid ability to fund operations and future growth. Analysts have set a mean price target of $3.17, with a median of $3.17, suggesting a consensus on moderate growth potential.
The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is further supported by the absence of significant share issuance activity in the recent financial data. The company's capital structure is stable, with minimal long-term debt and a strong equity base.
Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's financial health and operational performance remain consistent with its historical trends, and there are no notable regulatory or market disruptions reported in the latest filings.
- CGS.AX has a strong liquidity position with a current ratio of 3.77 and a low debt-to-equity ratio of 0.01.
- The company's profitability is robust, with a return on equity of 21.18% and a return on assets of 15.66%.
- CGS.AX's revenue is primarily derived from healthcare diagnostics services, with no disclosed geographic diversification.
- Analysts project a mean price target of $3.17, indicating moderate growth expectations.
- The company's risk profile is low, with no immediate liquidity or dilution concerns.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,07 |
| Revenue | —no estimate | —no estimate | 59,9M USD |
| Operating income | —no estimate | —no estimate | 14,4M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- CGS.AX Market data — financials · 2026-05-27
- CogState Ltd Market data — analyst estimates · 2026-05-27